Guided Therapeutics Q2 2026: Wider Losses, $12K Cash, Going Concern Warning Reiterated
GTHP has more than doubled off its 52-week low of $0.086 on light trading volume (0.3× avg).
Summary
Guided Therapeutics' Q2 2026 report shows a $604K quarterly loss, cash of only $12K, and a reiterated going concern warning. The company needs $2.4M over the next year and continues to rely on dilutive financing.
Key Events · Earnings and Guidance · GTHP
-
Q2 2026 Net Loss
Net loss attributable to common stockholders was $604 thousand for Q2 2026, compared to $856 thousand in Q2 2025. Six-month loss was $1.6 million, up from $1.3 million in the prior-year period.
-
Cash Position Deteriorates
Cash and cash equivalents fell to $12 thousand as of June 30, 2026, from $63 thousand at December 31, 2025. Working capital deficit was $5.6 million.
-
Going Concern Warning Reiterated
The company states substantial doubt about its ability to continue as a going concern. It estimates needing approximately $2.4 million over the next 12 months to fund operations and FDA approval efforts.
-
Material Weakness in Internal Controls
Disclosure controls and procedures were ineffective as of June 30, 2026, due to material weaknesses related to lack of resources for complex transactions and inadequate board oversight of significant transactions.
Analysis · GTHP · Industrial Applications And Services
Guided Therapeutics reported a net loss attributable to common stockholders of $604 thousand for Q2 2026, bringing the six-month loss to $1.6 million. Cash has dwindled to just $12 thousand, and the company reiterates substantial doubt about its ability to continue as a going concern. The company needs approximately $2.4 million over the next 12 months and continues to rely on dilutive convertible notes and warrant exercises to fund operations. A material weakness in internal controls was also disclosed. While the FDA clinical trial results were filed in June 2026, approval remains uncertain, and the company's survival hinges on raising additional capital on acceptable terms.
At the time of this filing, GTHP was trading at $0.29 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $28M. The 52-week trading range was $0.09 to $0.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.